Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

bsequent 12-week study period.

Anthony A. DiTonno, President and CEO, commented, "I am very pleased with our ability to complete the enrollment of this study ahead of plan. When we completed our initial public offering earlier this year, we indicated that we would file a new drug application (NDA) with the Food and Drug Administration (FDA) in the second half of 2008. Completion of enrollment in this study, on top of our three already completed successful Phase 3 trials, increases our confidence that we can meet this goal."

NeurogesX has successfully completed two Phase 3 studies in postherpetic neuralgia (PHN) and one in HIV-DSP. NGX-4010 has been granted orphan status and has received fast track designation from the FDA for HIV-DSP. NeurogesX believes that it is on track to file for marketing approval in the European Union before the end of 2007 for a broad indication of peripheral neuropathic pain. The Company is currently evaluating various regulatory filing strategies in the United States in order to most efficiently seek FDA approval of both the PHN and HIV-DSP indications, and believes that it will be able to submit a new drug application with the FDA in 2008.

About PHN and HIV-DSP

PHN is a painful condition affecting sensory nerve fibers. It is a complication of shingles, a second outbreak of the varicella-zoster virus, which initially causes chickenpox. Following an initial infection, some of the virus can remain dormant in nerve cells. Years later, age, illness, stress, medications or other factors that are not well understood can lead to reactivation of the virus. The rash and blisters associated with shingles usually heal within six weeks, but some people continue to experience pain for years thereafter. This pain is known as postherpetic neuralgia. PHN may occur in almost any area, but is especially common on the torso.

HIV-DSP is caused primarily by three factors: direct activation of cells known as sensory neurons by the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... ON , Feb. 27, 2015 /CNW/ - Covalon Technologies ... medical technologies company, today announced financial results for its ... For the three months ended December 31, 2014, revenue ... the quarter was $229,820 or $0.02 per share.  ... , said "I am very pleased with the significant ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/26/2015)... CLARA, Calif. , Feb. 27, 2015  Finesse expands ... Finesse Solutions announced the expansion of its ... opening is planned for mid-March and access for customers ... from the A-563, and located adjacent to the current ... by the Finesse automation engineering team and allow Finesse to ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2
... Sept. 23, 2011 Solos Endoscopy, Inc.,s (OTCPK: SNDY) ... a new website and will begin marketing its MammoView® ... direct sales channels and social media. MammoView® ... are all featured on the Company,s website http://www.solosendoscopy.com/newproductline.html ...
... The U.S. Food and Drug Administration today approved Soliris ... (aHUS), a rare and chronic blood disease that can ... with increased risk of death and stroke. ... HUS accounts for 5 to 10 percent of all ...
Cached Medicine Technology:Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals 2FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
(Date:2/28/2015)... A case management conference ( http://www.testosteronelawsuithub.com/ ... filed by law firms including Bernstein Liebhard LLP has ... Firm notes. , According to a Calendar posted ... litigation will meet on March 13, 2015 at 1:30 ... designed to raise levels of the male hormone. The ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an article ... To Steal Your Data , which stresses the ease with ... DIY phishing kit, or any kind of malware kit for ... point about how everyone’s cyber security is intertwined when it ... legitimate content management systems or blogs in order to install ...
(Date:2/28/2015)... Developers of FCPX plugins and ... plugin for Final Cut Pro X entitled FCPX Overlay Chromatic ... gives users total control over 6k lens dirt overlays inside ... Film Studios. “FCPX Overlay Chromatic was professionally designed to add ... , FCPX Overlay Chromatic Grunge 6K is a resourceful tool ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Plugin creators ... TransFold Volume 2. A fully customizable transition ... “TransFold Volume 2 gives users total control over 30 ... Austin, CEO of Pixel Film Studios. “TransFold Volume 2 ... editor.” , TransFold Volume 2 from Pixel Film Studios ...
(Date:2/28/2015)... February 28, 2015 My Shiney Hiney® LLC., ... a team to Las Vegas, Nevada for the annual ASD ... one of the leading consumer-goods tradeshows and My Shiney Hiney ... year’s event. My Shiney Hiney can be found at booth ... design for the at-home personal hygiene brush and cleansing system ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... the theory that deformed proteins are to blame for ... Mad Cow disease and other related brain disorders// may ... misshapen proteins, known as prions, that scientists think are ... particles in mouse nerve cells infected with two brain-wasting ...
... review of the latest clinical trials, coronary artery bypass surgery ... heart-lung machine//, is a safe option that leads to fewer ... in Journal of Cardiac Surgery. ,“Previously, it ... on the heart by stopping the heart and passing the ...
... survey, many Britishers are resorting to drinking to get rid ... the main reasons// attributed to stress. ,This survey ... of sixteen and above. Fifty one percent of them revealed ... eight percent felt it was work which was stressing them ...
... pollutants, are at a higher risk of cardiovascular problems ... ,The study conducted by Women’s Health Initiative, which is ... findings that urge the Environmental Protection Agency (EPA) to ... ,Though the EPA had tightened its daily limit for ...
... It may be described as a ‘drop in the bucket’ by ... the 25 million dollar fund allocated to the// treatment of first ... son of a police officer who succumbed to pulmonary fibrosis, supposedly ... Centre (WTC) has reported results of his meeting with the president ...
... The rapidly climbing obesity rates in the United States ... to reflux disease. And this has some surgeons wondering// ... is as safe in obese patients. ,According ... Health System, obese patients who underwent a procedure called ...
Cached Medicine News:Health News:Virus may Be the Cause of Mad Cow 2Health News:Stakes Higher for Elderly Women Exposed to Air Pollution 2Health News:More Money to Flow for First Responders at Ground Zero 2Health News:Esophageal Cancer Rates Climb With Obesity 2Health News:Esophageal Cancer Rates Climb With Obesity 3